Lilly to acquire ImClone; Bristol abandons buyout bid

10/6/2008 | Bloomberg · Reuters

Eli Lilly and Co. confirmed that it will pay $6.5 billion to take over ImClone Systems, maker of cancer treatment Erbitux. The move allows Lilly to expand its pipeline as it prepares to counter generic competition for Zyprexa, a top-selling schizophrenia drug. Bristol-Myers Squibb said it expects to get about $1 billion by selling its shares in ImClone, but it will continue to co-market Erbitux in the U.S.

View Full Article in:

Bloomberg · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY